Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: $0.47 to $0.51
• 50-Day Range: $0.51 to $0.79
• 52-Week Range: $0.47 to $1.53
• Volume: 500,950 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $42.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Buy

Oncolytics Biotech Stock Analysis - MarketRank™

Oncolytics Biotech scored higher than 24% of companies evaluated by MarketBeat, and ranked 812th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oncolytics Biotech has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.28) to ($0.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncolytics Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncolytics Biotech is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncolytics Biotech has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.51% of the float of Oncolytics Biotech has been sold short.

Short Interest Ratio / Days to Cover

Oncolytics Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncolytics Biotech has recently increased by 1.01%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncolytics Biotech does not currently pay a dividend.

Dividend Growth

Oncolytics Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.51% of the float of Oncolytics Biotech has been sold short.

Short Interest Ratio / Days to Cover

Oncolytics Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncolytics Biotech has recently increased by 1.01%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

8 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of Oncolytics Biotech is held by insiders.

Percentage Held by Institutions

Only 6.82% of the stock of Oncolytics Biotech is held by institutions.

ONCY Stock Analysis - Frequently Asked Questions

How have ONCY shares performed this year?

Oncolytics Biotech's stock was trading at $0.9138 on January 1st, 2025. Since then, ONCY stock has decreased by 45.5% and is now trading at $0.4980.
View the best growth stocks for 2025 here.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its earnings results on Friday, November, 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.03.

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), QUALCOMM (QCOM) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 11/03/2023
• Today: 4/04/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCY
• CIK: 1129928
• Web: www.oncolyticsbiotech.com
• Phone: (403) 670-7377
• Fax: 403-283-0858
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.33
• High Stock Price Target: $5.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +746.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,560,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.15%
• Return on Assets: -84.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.99
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 86,422,000
• Free Float: 85,415,000
• Market Cap: $44.25 million
• Optionable: Not Optionable
• Beta: 1.07